These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 24692701)

  • 21. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice.
    Piccioni F; Malvicini M; Garcia MG; Rodriguez A; Atorrasagasti C; Kippes N; Piedra Buena IT; Rizzo MM; Bayo J; Aquino J; Viola M; Passi A; Alaniz L; Mazzolini G
    Glycobiology; 2012 Mar; 22(3):400-10. PubMed ID: 22038477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
    Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
    AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
    Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
    Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal co-delivered oleanolic acid attenuates doxorubicin-induced multi-organ toxicity in hepatocellular carcinoma.
    Sarfraz M; Afzal A; Raza SM; Bashir S; Madni A; Khan MW; Ma X; Xiang G
    Oncotarget; 2017 Jul; 8(29):47136-47153. PubMed ID: 28525367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
    Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
    J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor vasculature-targeted recombinant mutated human TNF-α enhanced the antitumor activity of doxorubicin by increasing tumor vessel permeability in mouse xenograft models.
    Jiang C; Niu J; Li M; Teng Y; Wang H; Zhang Y
    PLoS One; 2014; 9(1):e87036. PubMed ID: 24466321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
    Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
    Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
    Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
    Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
    Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
    Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
    Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
    Piguet AC; Semela D; Keogh A; Wilkens L; Stroka D; Stoupis C; St-Pierre MV; Dufour JF
    J Hepatol; 2008 Jul; 49(1):78-87. PubMed ID: 18486258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergism of hydroxyapatite nanoparticles and recombinant mutant human tumour necrosis factor-alpha in chemotherapy of multidrug-resistant hepatocellular carcinoma.
    Li G; Dong S; Qu J; Sun Z; Huang Z; Ye L; Liang H; Ai X; Zhang W; Chen X
    Liver Int; 2010 Apr; 30(4):585-92. PubMed ID: 19780956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma].
    Liu CL; Tang CW; Zhou XC
    Zhonghua Nei Ke Za Zhi; 2003 May; 42(5):313-5. PubMed ID: 12882711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of silymarin and silymarin-doxorubicin applications on telomerase activity of human hepatocellular carcinoma cell line HepG2.
    Yurtcu E; Darcansoy Iseri O; Iffet Sahin F
    J BUON; 2015; 20(2):555-61. PubMed ID: 26011349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gene transfection of endostatin synergizes with doxorubicin to suppress human hepatocellular carcinomas: experiment with mice].
    Liu FJ; Tan G; Li J; Sun XY
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2147-51. PubMed ID: 19080480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy.
    Gong Y; Wu X; Wang T; Zhao J; Liu X; Yao Z; Zhang Q; Jian X
    Oncotarget; 2017 Jun; 8(25):40454-40468. PubMed ID: 28465466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.